Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Herzog Highlights Approval of Olaparib/Bevacizumab as Frontline Maintenance in HRD+ Ovarian Cancer

May 9th 2020

Thomas Herzog, MD, discusses the FDA approval of olaparib plus bevacizumab for the frontline maintenance treatment of patients with homologous recombination deficiency–positive ovarian cancer.

Dr. Naumann on Unanswered Questions With PARP Inhibitors in Ovarian Cancer

May 6th 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses unanswered questions with PARP inhibitors in ovarian cancer.

Dr. Coleman on Recent Advances and Remaining Questions in Ovarian Cancer

May 5th 2020

Robert L. Coleman, MD, FACOG, FACS, discusses recent advances made in the treatment of patients with ovarian cancer and remaining questions regarding the role of immunotherapy.

Naumann on Navigating the FDA Approval of Niraparib in Ovarian Cancer

May 4th 2020

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

PARP Inhibitor Trials Revolutionize Frontline Ovarian Cancer

May 4th 2020

Transformative clinical trials of PARP inhibitors have revolutionized the frontline treatment paradigm in advanced ovarian cancer.

Innovative Combo Regimens Are Necessary in Heterogeneous Ovarian Cancer Population

May 3rd 2020

Strategies with PARP inhibitors in ovarian cancer should focus on combination strategies to more effectively treat a heterogeneous patient population.

Optimal Sequencing Remains a Hurdle in Ovarian Cancer Treatment

May 3rd 2020

The surge of treatment options for patients with ovarian cancer poses a daunting challenge as answers for optimal sequencing continue to elude clinicians.

RAF-MEK Inhibitor/Defactinib Combo Is Active in KRAS-Mutant Cancers

April 30th 2020

The combination of the RAF-MEK inhibitor VS-6766 (CH5126766) and the FAK inhibitor defactinib (VS-6063) elicited early signals of clinical activity in a group of patients with KRAS-mutant advanced cancers.

Dr. Lewin on the Addition of HIPEC to Interval Cytoreductive Surgery in Ovarian Cancer

April 28th 2020

Sharyn Lewin, MD, FACS, discusses the utility of hyperthermic intraperitoneal chemotherapy in newly diagnosed advanced-stage ovarian cancer.

Observing Optimal Treatment Strategies in Ovarian Cancer in Ohio

April 23rd 2020

We recently traveled to Columbus, Ohio for a State of the Science Summit™ on Ovarian Cancer, which featured insights from The Ohio State University Comprehensive Cancer Center–James faculty.

Dr. O'Malley on Antitumor Activity With Veliparib Combo in Serous Ovarian Cancer

April 22nd 2020

David O'Malley, MD, discusses antitumor activity with veliparib in combination with chemotherapy in patients with high grade serous ovarian cancer.

The State of Ovarian Cancer: Hot Topics in the COVID-19 Pandemic

April 17th 2020

An OncLive® Weekly Webinar Series highlighting best practices, treatment updates, and multidisciplinary approaches to ovarian cancer care through the COVID-19 pandemic. Join us Wednesday, June 3, 2020 at 8 PM EST.

The State of Ovarian Cancer: Exploring the Landscape of Systemic Therapy

April 16th 2020

In this third webinar of our series, we will take an in-depth look at systemic therapy and how the landscape of treatment continues to evolve during this time. Join us on Wednesday, May 20, 2020 at 8 PM EST.

The State of Ovarian Cancer: Surgical Practices and Management

April 15th 2020

Analyses Underscore Extent of Frontline Maintenance Niraparib Benefit in Ovarian Cancer

April 11th 2020

The success of frontline maintenance niraparib in the phase III PRIMA trial extends to meeting biomarker-defined and other secondary endpoints and showing positive patient-reported outcomes.

Dr. O'Malley on Increased Benefit of Rucaparib Maintenance in RAD51C/D-Mutant Ovarian Cancer

April 10th 2020

David O'Malley, MD, discusses the increased benefit of rucaparib maintenance in patients with ovarian cancer who express RAD51C/D mutations.

Dr. Swisher on the Implications of the VELIA Trial in Ovarian Cancer

April 10th 2020

Elizabeth M. Swisher, MD, discusses the implications of the phase III VELIA/GOG-3005 trial in ovarian cancer.

Dr. O'Malley on Maintenance Rucaparib in Non-BRCA HRR-Mutated Ovarian Cancer

April 9th 2020

David O’Malley, MD, discusses the rationale to evaluate the clinical benefit of rucaparib maintenance treatment following disease progression in a subgroup of patients with ovarian cancer whose disease is associated with a mutation in a non-BRCA homologous recombination gene in the phase III ARIEL3 trial in ovarian cancer.

Pazopanib Plus Oral Cyclophosphamide Shows Benefit in Platinum-Resistant Epithelial Ovarian Cancer

April 9th 2020

Pazopanib plus oral cyclophosphamide is a well-tolerated regimen that has clinically relevant benefit in patients with platinum-resistant or -refractory epithelial ovarian cancer, according to results from a retrospective study published in the Journal of Clinical Oncology.

Dr. Comerci on the Use of Laparoscopy in Ovarian Cancer

April 9th 2020

John T. Comerci, MD, associate professor, University of Pittsburgh School of Medicine, and director of Gynecologic Oncology, University of Pittsburgh Medical Center Passavant Hospital, discusses the use of laparoscopy in ovarian cancer.